These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7587998)

  • 21. [Critical analysis of controlled pharmacologic studies in obsessive compulsive disorder].
    Brochier T; Hantouche E
    Encephale; 1989; 15(3):325-33. PubMed ID: 8641159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder.
    Kumar TC; Khanna S
    Aust N Z J Psychiatry; 2000 Jun; 34(3):527-8. PubMed ID: 10881981
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.
    Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S
    J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
    Koran LM; Mueller K; Maloney A
    J Clin Psychopharmacol; 1996 Jun; 16(3):253-4. PubMed ID: 8784659
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors.
    Vythilingum B; Cartwright C; Hollander E
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S7-13. PubMed ID: 11110014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence-based pharmacotherapy of obsessive-compulsive disorder.
    Fineberg NA; Gale TM
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):107-29. PubMed ID: 15450126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pareidolias in obsessive-compulsive disorder: neglected symptoms that may respond to serotonin reuptake inhibitors.
    Fontenelle LF
    Neurocase; 2008; 14(5):414-8. PubMed ID: 18850462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder.
    Ackerman DL; Greenland S
    J Clin Psychopharmacol; 2002 Jun; 22(3):309-17. PubMed ID: 12006902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
    López-Ibor JJ; Saiz J; Cottraux J; Note I; Viñas R; Bourgeois M; Hernández M; Gómez-Pérez JC
    Eur Neuropsychopharmacol; 1996 May; 6(2):111-8. PubMed ID: 8791036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic therapy of obsessive compulsive disorder.
    DeVeaugh-Geiss J
    Adv Pharmacol; 1994; 30():35-52. PubMed ID: 7833296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
    Ellingrod VL
    Pharmacotherapy; 1998; 18(5):936-60. PubMed ID: 9758307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blepharospasm as an obsessive-compulsive phenomenon.
    Jain M; Aggarwal A; Khandelwal A
    J Neuropsychiatry Clin Neurosci; 2011; 23(2):E19-20. PubMed ID: 21677211
    [No Abstract]   [Full Text] [Related]  

  • 35. Breakthrough in psychiatric care: pharmacological treatment of obsessive-compulsive disorders with implications for nursing care.
    Giger JN; Davidhizar R; Poole VL
    J Pract Nurs; 2002; 52(2):12-6; quiz 17, 21. PubMed ID: 12122747
    [No Abstract]   [Full Text] [Related]  

  • 36. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.
    Koran LM; Sallee FR; Pallanti S
    Am J Psychiatry; 1997 Mar; 154(3):396-401. PubMed ID: 9054789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sertraline: new indication. May help children with obsessive-compulsive disorder.
    Prescrire Int; 2002 Jun; 11(59):69-72. PubMed ID: 12068839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.